AMENDMENT NO. 2 TO LICENSE AND SUPPLY AGREEMENTLicense and Supply Agreement • March 1st, 2013 • Endo Health Solutions Inc. • Pharmaceutical preparations
This Amendment No. 2 to License and Supply Agreement (this “Amendment”) is entered into with effect as of December 31, 2012 (“Amendment Effective Date”), by and among Endo Pharmaceuticals Inc., a Delaware corporation having a principal place of business at 100 Endo Drive, Chadds Ford, Pennsylvania 19317 (“Endo”), Novartis Consumer Health, Inc., a Delaware corporation having a principal place of business at 200 Kimball Drive, Parsippany, New Jersey 07054 (“Novartis”), and Novartis AG, a Swiss corporation having a principal place of business in Basel, Switzerland (“Novartis AG”). Each of Novartis AG, Novartis and Endo is referred to herein individually as a “Party” and collectively as the “Parties.”
ENDO HEALTH SOLUTIONS INC. STOCK AWARD AGREEMENTStock Award Agreement • March 1st, 2013 • Endo Health Solutions Inc. • Pharmaceutical preparations • Delaware
This Stock Award Agreement (this "Award Agreement"), is made and entered into as of the date of grant set forth below (the "Date of Grant") by and between Endo Health Solutions Inc., a Delaware corporation (the "Company"), and the participant named below (the "Participant"). Capitalized terms not defined herein shall have the meanings ascribed to them in the Endo Health Solutions Inc. Assumed Stock Incentive Plan (the "Plan"). Where the context permits, references to the Company shall include any successor to the Company.
ENDO HEALTH SOLUTIONS INC. ENDO STOCK AWARD AGREEMENT UNDER THE 2010 STOCK INCENTIVE PLANStock Award Agreement • March 1st, 2013 • Endo Health Solutions Inc. • Pharmaceutical preparations • Delaware
This Endo Stock Award Agreement (this “Award Agreement”), is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Endo Health Solutions Inc., a Delaware corporation (the “Company”), and the participant named below (the “Participant”). Capitalized terms not defined herein shall have the meanings ascribed to them in the Endo Health Solutions Inc. 2010 Stock Incentive Plan (the “Plan”). Where the context permits, references to the Company shall include any successor to the Company.
ENDO HEALTH SOLUTIONS INC. STOCK OPTION AGREEMENTStock Option Agreement • March 1st, 2013 • Endo Health Solutions Inc. • Pharmaceutical preparations • Delaware
This Stock Option Agreement (this “Option Agreement”) is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Endo Health Solutions Inc., a Delaware corporation (the “Company”), and the optionee named below (the “Optionee”). Capitalized terms not defined herein shall have the meaning ascribed to them in the Company’s 2010 Stock Incentive Plan (the “Plan”). Where the context permits, references to the Company shall include any successor to the Company.
TERMINATION AGREEMENTTermination Agreement • March 1st, 2013 • Endo Health Solutions Inc. • Pharmaceutical preparations • New York
This Termination Agreement (this “Termination Agreement”) is entered into as of December 31, 2012 (“Termination Date”), by and between Endo Pharmaceuticals Inc., a Delaware corporation having a principal place of business at 100 Endo Drive, Chadds Ford, Pennsylvania 19317 (“Endo”), and Novartis Consumer Health, Inc., a Delaware corporation having a principal place of business at 200 Kimball Drive, Parsippany, New Jersey 07054 (“NCH”). Each of NCH and Endo is referred to herein individually as a “Party” and collectively as the “Parties.”
ENDO HEALTH SOLUTIONS INC. STOCK OPTION AGREEMENTStock Option Agreement • March 1st, 2013 • Endo Health Solutions Inc. • Pharmaceutical preparations • Delaware
This Stock Option Agreement (this “Option Agreement”) is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Endo Health Solutions Inc., a Delaware corporation (the “Company”), and the optionee named below (the “Optionee”). Capitalized terms not defined herein shall have the meaning ascribed to them in the Endo Health Solutions Inc. Assumed Stock Incentive Plan (the “Plan”). Where the context permits, references to the Company shall include any successor to the Company.
FIRST AMENDMENT TO DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • March 1st, 2013 • Endo Health Solutions Inc. • Pharmaceutical preparations
This First Amendment to Development, License and Supply Agreement (this “Amendment”) is entered into as of December 19, 2012 (“Date of Amendment”) by and between ENDO PHARMACEUTICALS INC., a Delaware corporation, with its principal offices located at 100 Endo Boulevard, Chadds Ford, Pennsylvania 19317, United States of America (“ENDO”) and Grünenthal GMBH, a company having its principal office at Zieglerstraße 6, 52078 Aachen, Federal Republic of Germany (“GRÜNENTHAL”). ENDO and GRÜNENTHAL may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Agreement.
